Population
Cardiac K channels encoded by hERG, rKv1.4, rKv4.3, and hKvLQT1 along with hIsK
Design
Preclinical
Authors
Loading...
May inform bupivacaine cardiotoxicity risk in vulnerable patients; leaves open translation of channel-specific effects to human arrhythmia models.
Bupivacaine acts as a nonspecific pore blocker on cardiac K channels, with its binding affinity and voltage dependence modulated by channel inactivation processes and subunit composition.
Lipka et al. (1998) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: